Travere Therapeutics, Inc. Common Stock (TVTX) Stock Price

TVTXStock

$65.67+271.02%52W

Market Cap$6.19B

P/E—

PEG Ratio—

Div yield—

Beta1.11

TVTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)100.73%

Price vs S&P 500 (4W)17.90%

VGM Score61.40

P/CF (Annual)153.25x

Book Value / Share (Quarterly)$0.26

P/TBV (Annual)1995.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)32.28%

Cash Flow / Share (Quarterly)$0.16

Price vs S&P 500 (YTD)59.04%

Gross Margin (TTM)98.60%

Net Profit Margin (TTM)-7.35%

EPS (TTM)$-0.50

10-Day Avg Trading Volume1.21M

EPS Excl Extra (TTM)$-0.50

Revenue Growth (5Y)19.87%

EPS (Annual)$-0.29

ROI (Annual)-5.99%

Gross Margin (Annual)97.89%

Net Profit Margin (5Y Avg)-86.07%

Cash / Share (Quarterly)$5.19

Revenue Growth QoQ (YoY)48.17%

ROA (Last FY)-4.22%

Revenue Growth TTM (YoY)77.12%

EBITD / Share (TTM)$0.23

ROE (5Y Avg)-266.16%

Operating Margin (TTM)-6.84%

Cash Flow / Share (Annual)$-0.22

P/B Ratio236.13x

P/B Ratio (Quarterly)215.44x

Net Income / Employee (Annual)$-51,400

EV / Revenue (TTM)10.61x

Net Interest Coverage (TTM)-54.64x

ROA (TTM)-6.96%

EV / EBITDA (TTM)294.53x

EPS Incl Extra (Annual)$-0.29

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)3.75x

3-Month Avg Trading Volume1.95M

52-Week Price Return271.02%

Revenue / Employee (TTM)$1,189,800

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)11.80x

Asset Turnover (Annual)0.81x

52-Week High$67.85

Operating Margin (5Y Avg)-123.87%

EPS Excl Extra (Annual)$-0.29

CapEx CAGR (5Y)18.81%

Tangible BV CAGR (5Y)-58.03%

26-Week Price Return112.66%

Quick Ratio (Annual)2.52x

13-Week Price Return37.50%

Total Debt / Equity (Annual)2.71x

Current Ratio (Quarterly)4.05x

Enterprise Value$6.28B

Revenue / Share Growth (5Y)5.67%

Asset Turnover (TTM)0.95x

Book Value / Share Growth (5Y)-20.77%

Revenue / Employee (Annual)$987,400

Inventory Turnover (Annual)1.71x

Pretax Margin (Annual)-10.04%

Cash / Share (Annual)$3.55

3-Month Return Std Dev42.80%

Gross Margin (5Y Avg)96.02%

Net Income / Employee (TTM)$-87,500

ROE (Last FY)-22.25%

Net Interest Coverage (Annual)0.10x

EPS Basic Excl Extra (Annual)$-0.29

P/FCF (TTM)73.47x

Receivables Turnover (TTM)9.91x

EV / Free Cash Flow (TTM)407.53x

Total Debt / Equity (Quarterly)24.58x

EPS Incl Extra (TTM)$-0.50

Receivables Turnover (Annual)9.15x

ROI (TTM)-9.40%

P/S Ratio (TTM)9.79x

Pretax Margin (5Y Avg)-123.33%

Revenue / Share (Annual)$5.50

Tangible BV / Share (Annual)$0.02

Forward P/E56.23x

Price vs S&P 500 (52W)252.46%

Year-to-Date Return71.87%

5-Day Price Return0.69%

EPS Normalized (Annual)$-0.29

ROA (5Y Avg)-27.41%

Net Profit Margin (Annual)-5.21%

Month-to-Date Return17.50%

Cash Flow / Share (TTM)$-4.45

EBITD / Share (Annual)$-0.04

Operating Margin (Annual)-12.80%

LT Debt / Equity (Annual)2.71x

P/CF (TTM)62.46x

ROI (5Y Avg)-39.86%

LT Debt / Equity (Quarterly)24.58x

EPS Basic Excl Extra (TTM)$-0.50

P/TBV (Quarterly)1995.76x

P/B Ratio (Annual)29.77x

Inventory Turnover (TTM)1.39x

Pretax Margin (TTM)-11.34%

Book Value / Share (Annual)$1.26

Price vs S&P 500 (13W)35.55%

Beta1.11x

Revenue / Share (TTM)$6.33

ROE (TTM)-55.79%

52-Week Low$17.27

vGradeF

gGradeB

mGradeA

vgmGradeB

TVTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	$0.32	-$0.10	-131.02%(-$0.42)
Q1 2026	May 4, 2026	-$0.06	$0.05	+187.00%(+$0.11)
Q4 2025	Feb 19, 2026	$0.37	$0.37	-0.77%(-$0.00)
Q3 2025	Oct 30, 2025	-$0.09	$0.59	+794.12%(+$0.67)
Q2 2025	Aug 6, 2025	$0.04	$0.13	+225.00%(+$0.09)

TVTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.54

About Travere Therapeutics, Inc. Common Stock

Travere Therapeutics is a biopharmaceutical company developing therapies for rare kidney, liver, and metabolic diseases. Its lead candidate, sparsentan, is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can progress to end-stage kidney disease. The company is also advancing pegtibatinase, an investigational enzyme replacement therapy for HCU, a genetic metabolic disorder.